CIP
VRTX icon

Chartwell Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Chartwell Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,927
Closed -$3.85M – 432
2023
Q2 		$3.85M Buy
10,927
+1,038
+10% +$350K 0.14% 228
2023
Q1 		$3.12M Hold
9,889
– – 0.12% 237
2022
Q4 		$2.86M Buy
9,889
+6,399
+183% +$1.95M 0.11% 236
2022
Q3 		$1.01M Hold
3,490
– – 0.04% 348
2022
Q2 		$983K Sell
3,490
-4,055
-54% -$1.09M 0.04% 358
2022
Q1 		$1.97M Buy
7,545
+441
+6% +$105K 0.07% 298
2021
Q4 		$1.56M Buy
7,104
+1,703
+32% +$331K 0.05% 342
2021
Q3 		$980K Hold
5,401
– – 0.03% 379
2021
Q2 		$1.09M Sell
5,401
-10,487
-66% -$2.19M 0.03% 368
2021
Q1 		$3.42M Sell
15,888
-1,553
-9% -$341K 0.1% 233
2020
Q4 		$4.12M Sell
17,441
-4,531
-21% -$1.04M 0.13% 211
2020
Q3 		$5.98M Buy
21,972
+1,667
+8% +$460K 0.22% 162
2020
Q2 		$5.89M Buy
20,305
+611
+3% +$166K 0.23% 168
2020
Q1 		$4.69M Sell
19,694
-245
-1% -$56.2K 0.22% 164
2019
Q4 		$4.37M Sell
19,939
-24
-0.1% -$4.86K 0.14% 200
2019
Q3 		$3.38M Sell
19,963
-371
-2% -$65.6K 0.11% 242
2019
Q2 		$3.73M Sell
20,334
-2,188
-10% -$383K 0.12% 239
2019
Q1 		$4.14M Sell
22,522
-3,769
-14% -$696K 0.13% 229
2018
Q4 		$4.36M Buy
26,291
+2,689
+11% +$466K 0.15% 203
2018
Q3 		$4.55M Buy
23,602
+3,151
+15% +$561K 0.13% 229
2018
Q2 		$3.48M Buy
20,451
+13,765
+206% +$2.13M 0.1% 264
2018
Q1 		$1.09M Buy
6,686
+42
+0.6% +$6.86K 0.04% 369
2017
Q4 		$996K Sell
6,644
-4,418
-40% -$654K 0.03% 385
2017
Q3 		$1.68M Buy
11,062
+7,690
+228% +$1.16M 0.06% 341
2017
Q2 		$435K Buy
+3,372
New +$406K 0.02% 399
2017
Q1 		– Sell
-9,375
Closed -$691K – 447
2016
Q4 		$691K Sell
9,375
-60,340
-87% -$4.91M 0.02% 387
2016
Q3 		$6.08M Buy
+69,715
New +$6.59M 0.11% 227
2013
Q4 		– Sell
-88,630
Closed -$6.72M – 372
2013
Q3 		$6.72M Buy
+88,630
New +$7.05M 0.15% 225

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chartwell Investment Partners's VRTX Position: Q3 2023 in Review

Chartwell Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 10,927 shares — an estimated $3.85M sold.

Chartwell Investment Partners first reported a position in VRTX in Q3 2013 and held it in 28 quarters. The position peaked at $6.72M in Q3 2013. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Chartwell Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Chartwell Investment Partners sold 10,927 Vertex Pharmaceuticals shares in Q3 2023, an estimated $3.85M.
  • Chartwell Investment Partners first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 28 quarters.
  • Chartwell Investment Partners's Vertex Pharmaceuticals position peaked at $6.72M in Q3 2013.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Chartwell Investment Partners's 13F filing for Q3 2023, filed 7 Nov 2023.